Akums Drugs signs a long-term CDMO contract worth ₹1,760 crore with a leading global pharma player

Akums will commence the commercial supply of this products in 2027 and this will go on till 2032. The company will also initiate European approvals of its oral liquid site, which it intends to leverage to manufacture these products.

Leave a Reply

Your email address will not be published. Required fields are marked *